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FOREWORD: 
ACADEMIC-INDUSTRY COLLABORATIONS IN THE CLINIC 
The "genetics revolution" has reached the clinic.1 Consequentially, clinical 
research has been infused with unprecedented innovation and potential for 
improving human health. 2 However, the maturation of contemporary biomedical 
research also has advanced an entanglement of ethical and regulatory 
complications associated with intense academic-industry collaboration, 
competition, and commercialization.3 Critics and many concerned participants 
claim that the life science communities and policy makers have launched this 
genetic revolution in science, and brought research into an era of academic­
industry alliances, without first establishing sufficient safeguards to ensure the 
protection of human subjects and the integrity of research. 4 �In response to this 
concern and related controversies which have captured media attention,5 the 
1. For identification of the drug development pipeline, see http:/ /www.phrma.org (last 
visited Aug. 23, 2001) (site of the Pharmaceutical Researchers and Manufacturers of America 
(PhRMA), the world's leading phannaceutical trade organization); http:/ /www.bio.org (last visited 
Aug. 23, 2001) (site of the Biotechnology Industry Organization (BIO), the world's leading 
biotechnology i ndustry trade organization); http:/ /www.clinicaltrials.gov (last visited Aug. 23, 2001) 
(details on approximately 5,SOO mostly government-funded clinical trials); http://cancertrials. 
nci.n ih.gov (last visited Aug. 23, 2001) (the National Cancer lnstitute's clinical trial li.�ting); 
http:/ /www.actis.org (last visited Aug. 23, 2001) (the AIDS clinical trial information service 
(ACTIS)); http:/ /www.centeiwatch.com (last visited Aug. 23, 2001) (one of the earliest and the 
most comprehensive private sites); http://www.emergingrned.com (last visited Aug. 23, 2001) 
(privately-funded cancer trials; under expansion to cover other diseases); http://www. 
veritasrnedicine.com Oast visited Aug. 23, 2001) (list� trials and standard treatments for numerous 
diseases); http:/ /www.americasdoctor.com (last visited Aug. 23, 2001) (trials in various disease 
categories, excluding cancer); and http:/ /www.acurian.com Qast visited Aug. 23, 2001) (developing 
lists of trials in numerous disease categories). 
2. S tt generai!J JlljJra note 1. 
3. S tt Press Release, Department of Health and Hum an Services, Secretary Shalala Bolsters 
Protections for Human Research Subjects (May 23, 2000) [hereinafter DHHS Press Release], 
avai/ab/eathttp://www.hhs.gov/news/press/2000pres/20000523.htrnl. Seea/soElizabethA.Boyd 
& Lisa A. Bero, Am;.sing F1Jt11/Jy Financial &latiomhips With Indmtry: A Cast St11tfy, 284 JAMA 2209 
(2000); Mildred K. Cho et al., Po/icie; on Faat/!y Conjlim of lnttml at US Uniwr.sititJ, 284 JAMA 2203 
(2000); Catherine D. DeAngelis, Conflid oflntemt and the P11b/i, Tf'llJI, 284 JAMA 2237 (2000). See 
gentral!J David Korn, Conjli&/; of Intm;t in Bio111 di&al RJJtarrh, 284 JAMA 2234 (2000). 
4. See, 1.g., DHHS Press Release, JlljJranote 3 (addressing the need to bolster protections for 
human subjects); Donna Shalala, Prottding &semrh S11Uj1as-What M11st Bt Drm, 343 NEW ENG. J. 
MED. 808 (2000). 
, 
S. The incident which has captured the most attention is the circumstances surrounding 
the death of Jesse Gelsinger, an 18-year-old gene-therapy subject in a protocol approved by the 
University of Pe nnsylvania. Stt Gelsinger v. Trustees of the Univ. of Pa., Case No. 000901885 (Ct. 
Corn. Pl., Phila. County, filed Sept. 18, 2000), athttp://www.ssluplaw.com/ l.inks/healthcare2.html 
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United States (including the government, industry, and academia sectors), is 
reassessing the soundness of its regulatory regimes to protect human subjects and 
research integrity.6 Consequentially, fundamental reform is being contemplated 
in t he midst of an extraordinary amount of important, ongoing clinical research.7 
On March 15, 2001, approximately 200 representatives from the biomedical 
industry, the medical conununity, government agencies, and multiple disciplines 
in academia gathered at the Widener University School of Law's Delaware 
campus to advance critical thinking about this pressing topic. This effort was a 
shared undertaking by the Widener Lzw SympoJium Journal and the Widener Health 
Law Institute in cooperation with the American Bar Association, Delaware Bar 
A ssociation, Pennsylvania Bar Association, Pennsylvania Biotechnology 
A ssociation, and with the financial sponsorship of Centocor, Inc. and Eckert 
Seamans Cherin & Mellott, LLC. 
The primary objective of the conference was to bridge legal academia with the 
life science and medical communities and to create a forum that could make a 
meaningful "real world" contribution through pragmatic discussion and by 
raising awareness. This issue of the Widener Law Sympoti11111 ]o111'11al contains a 
collection of written contributions originating from and complementing the livdy 
and informative conference proceedings. 
Oast visited Aug. 23, 2001); Thomas Petzinger Jr., Yes, Ttch11oloo S1t1111 to Cho11ge Almost Dai!J. B11t 
Some T mulr are Lllu!y Jo Remain in Force far 11 Ltmg Time, WAIL ST. J., Jan. 1, 2000, at R 12. 
6. The Department of Health & Human Services (DHHS), Office of the Secretary, hosted 
a forum on August 15-16, 2000, entitled "Human Subject Protection and Financial Conflict of 
Interest." This forum also was sponsored by the National Institutes of Health (NIH), Centers for 
Disease Control (CDC), and Food & Drug Administration (FDA). Sn Agenda. Human Subject 
Protection and Financial Conflicts of Interest Conference (Aug. 15, 2000), at http:/ I 
ohrp.osophs.dhhs.gov I coif a genda. httn. Subsequently, NIH undertook "visits" to recipient 
institutions throughout the country to see first-hand how they a.re dealing with conflicts of interest. 
See Patrick Healy, Ht1n1ard For11111 Eye.r Ovmight of BiometliMI &.r1arrh, BoSTON GLOBE, July 21, 2000, 
at A 13. More signjficantly, the FDA issued guidance to assist industry in dealing with potential 
conflicts of interests. FOOD & DRUG ADMJN., DEPT HEALrn & HUMAN SERVS., GUIDANCE FOR 
INDUSTRY: FINANCfAL DISCLOSURE BY CLINICAL INVESTIGATOR S (2001), 11/ 
http:/Iwww.fda.gov/ oc/ guidance/ financialdis.html (last visited Sept. 4, 2001). Along these same 
lines, representatives from several of the nation's top medical schools (Harvard, Baylor College of 
Medicine, Columbia University, Johns Hopkins University, the University of Pennsylvania, the 
Uni versity of Washington, Washington University, Yale University, and the University of California 
at San Francisco and Los Angeles) have jointly drafted proposed conflict of interest guidelines that 
require researchers to disclose any financial interests they have in studies involving patients. Ste 
Carey Goldberg, Medical School! Offer Ralls 011 Doctors' Co11flid of I 11tm.1t, N.Y. TIMES, Feb. 8, 2001, at 
A23. Several Professional Societies, including the American Society of Human Genetics, have done 
the same. s tt AMER. Soc'y OF GENE THERAPY (ASG1), POLICY OF THE AMERICAN SOCIETY OF 
GENE THERAPY ON FINANCIAL CONFLICT OF INTEREST IN CLINICAL REsEARCH (2000), at 
http://www.asgt.org/policy/index.html (last visited Sept. 4, 2001). 
7. See general!J supra note 1. 
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The issue begins with two overview pieces. First, in Financial Conflicts of Interest: 
How are we Managing?,8 Erica Rose surveys a multitude of fundamental issues 
introduced by financial conflicts of interest, including how conflicts of interest 
arise and attempts to identify and manage them. Second, in Globalization of 
Interests and Clinical R.esearch: An Overview of Trends and Issues,9 Timothy Caulfield 
surveys the trends of globalization and commercialization in clinical research 
relating to the issue of conflicts of interest. Caulfield sets forth several proposals, 
including the need to create research policy and Institutional Review Board 
structures to minimize conflicts and reduce the threat of forum shopping 
introduced by globalization.111 
The next four contributions focus on the roles and obligations of institutions, 
individual researchers, and involved physicians. In Institutional Conflicts and 
R.e.rponsibilities in an Age of Academic-Industry Alliances, 11 I focus on the impact of 
biotechnology and the genetics revolution on clinical research and the resulting 
issue of institutional conflicts of interest. I conclude that the issue of conflicts 
of interest transcends, and requires reforms to, the regulatory regimes for both 
technology transfer and human subject protections.12 I introduce several 
proposals for reform, the foremost being to write uniform, workable, and 
enforceable federal conflicts of interest standards directly into federal technology 
transfer policy.13 
Pilar Ossorio and Janet Aeetwood address the roles and responsibilities of 
clinical researchers. Ossorio's contribution, entitled Pills, Bills and Shills: Physician­
R.esearcher's Conflicts of Interest, is a primer on research, emphasizing the multi­
faceted nature and, consequentially, the varied roles of, and influences upon, 
physician-researchers.14 Ossorio offers suggestions to minimize and manage 
conflicts of interest, including the involvement of third parties in the consent 
process 15 and institutional policies for professional advancement which prioritize 
research quality over quantity. 16 Ossorio emphasizes the importance of 
disclosure and institutional oversight.17 
8. Erica Rose, Fina11aa/Conjlkts ojltrltmt: How an"" Managing?, 8 WIDENER L. SYMP. J. 1 
(2001). 
9. Timothy Caulfield, G�baliz.atio11 of Itrltmls and Cliniwl Rnearch: An Overview ofT rends and 
Imm, 8 WIDENER L. SYMP. J. 31 (2001). 
10. Stt id 
11. Michael J. Malinowski, Institlllional Conflitis and RupotrnbilititS in an Agt of Acadmric-lndNstry 
Alliatrtts, 8 WIDENER L. SYMP. J. 47 (2001). 
12. Su id 
13. Stt id at 69-70. 
14. Pilar N. Ossorio, Pills, Bills and Shi/J.r: Pl!Jsidan-&starchtr's Conflicts of Intmsl, 8 WIDENER 
L. SYMP. J. 75 (2001). 
15. Sttid at96-97. 
16. Id. at 97. 
17. Id at 100. 
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In Conflicts of Interest in Clinical &search: Advocating/or Patient-Subjects, Janet 
Fleetwood focuses on the doctor-patient relationship and the obligations to 
patient-subjects. Fleetwood attributes the ongoing nature of the conflicts of 
interest problem to three major factors: complications to the consent process 
attributable to the doctor-patient relationship, lack of sufficient subject-patient 
knowledge, and inadequate ongoing oversight by IRBs.18 She concludes that 
conflict of interest policies have done little to inform or protect patients.19 
The series of symposium articles concludes with a comprehensive treatment 
by Patricia Kuszler, entitled Curing Conflicts of Interest in Clinical &search: Impossible 
Dreams and Harsh Realities. 20 Kuszler surveys a broad range of conflicts issues, 
financial and non-financial, in basic research and the delivery of care as well as 
in clinical research. Kuszler concludes tha� "conflicts of interest, both financial 
and non-financial are now deeply embedded in the fabric of biomedical 
research"21 and, consequentially, "the traditional boundaries and values 
differential between the market and the ivory tower of academia are blurred, if 
not completely obliterated."22 
In addition to these pieces originating from the conference proceedings, this 
issue includes a book review by William Charles Lucas of Cynthia Robbins­
Roth's book, FROM ALCHEMY TO !PO: THE BUSINESS OF BIOTECHNOWGY. 2' 
In reviewing FROM ALCHEMY TO IPO, 24 a best-selling "industry insider's" 
account of the biotechnology sector, Lucas draws heavily from his own 
experience as the Vice President and Associate General Counsel of Pharmacia 
and former Vice President and General Counsel of Zeneca Pharmaceuticals. 
Lucas concludes that "the book ... provide[s] the potential investor with a 
helpful compendiwn of due diligence concerns and enough background to begin 
to understand this very complex industry."25 
Michael J. Malinowski 
Faculty Chair 
18. Janet Fleetwood, Conflict1 of Inteml in Clinical &mmh: Advocating far Politnt-S11ijec/1, 8 
WIDENER L. SYMP. J. 105, 105-06 (2001 ). 
19. Seeitl at 106. 
20. Patricia C. Kuszler, CmingConjlicuoflntemtin Clinical&mmh: Impouible Drran11 and Harsh 
Reolitie1, 8 WIDENER L. SYMP. J. 115 (2001). 
21. Id at 152. 
22. Id 
23. William Charles Lucas, From Alchemy to IPO: The B11sint11 ofBiot1&hnology, 8 WIDENER L. 
SYMP. J. 153 (2001) (book review). 
24. CYNTHIA ROBBINS-ROTH, FROM ALCHEMY TO IPO (2000). 
25. See Lucas, sttpra note 23, at 155. 
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